Search results for "From ACP Journal Club"
In uncontrolled T2DM treated with a basal-bolus insulin regimen, weekly icodec was noninferior to daily glargine for HbA1c at 26 wk
Weekly insulin injections might be optimal for patients with type 2 diabetes who are already taking weekly glucagon-like peptide 1 receptor agonists and need additional basal insulin, noted an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2023/08/11/6.htm
11 Aug 2023
In types 1 and 2 diabetes, weekly basal insulin Fc was noninferior to daily insulin degludec for HbA1c at 26 wk
The arrival of once-weekly insulin will undoubtedly be welcomed by patients and clinicians, but the advantages of fewer shots will have to be weighed against less flexibility in dosing of basal insulin, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2023/07/14/7.htm
14 Jul 2023
In T1DM, open-source automated insulin delivery increased glucose time in target vs. sensor-augmented pumps
A challenge to wider use of the open-source systems to manage type 1 diabetes (T1DM) is that they are not approved by the FDA and thus require clinicians to be willing to learn from and support their patients, said an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2023/01/13/9.htm
13 Jan 2023
In HFpEF, the benefit of empagliflozin on a composite of CV death or HF hospitalization at 26 mo did not vary by diabetes status
The combination of efficacy and safety data from a recent placebo-controlled trial and other research shows sodium-glucose cotransporter-2 inhibitors to be an important treatment for heart failure with preserved ejection fraction (HFpEF) regardless of patients' diabetes status, according to an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2022/10/14/6.htm
14 Oct 2022
In prediabetes, oral vitamin D reduces progression to new-onset diabetes
Other preventive treatments for patients with prediabetes may be more effective than this review found vitamin D to be, but vitamin supplementation has advantages of convenience, tolerability, availability, and cost over other options, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2023/05/12/8.htm
12 May 2023
In type 2 diabetes with increased CV risk, tirzepatide reduced HbA1c vs. glargine at 52 wk
Once tirzepatide is approved by the FDA, it may be a treatment option for patients with type 2 diabetes who are overweight, have high risk for atherosclerotic cardiovascular (CV) disease, and have no gastrointestinal symptoms, an ACP Journal Club summary said.
https://diabetes.acponline.org/archives/2022/03/11/7.htm
11 Mar 2022
In diabetes with no CVD, aspirin reduced serious vascular events but increased major bleeding at 7.4 years
The results of a recent trial of aspirin for cardiovascular disease (CVD) prevention in diabetes challenge current guidelines and the opinion of many clinicians of the net benefit of the drug, according to an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2019/01/11/6.htm
11 Jan 2019
KDIGO provided recommendations on SGLT2 inhibitors and nonsteroidal MRAs in patients with diabetes and CKD
Sodium-glucose cotransporter-2 (SGLT2) inhibitors and nonsteroidal mineralocorticoid receptor antagonists (MRAs) are now recommended for more patients with chronic kidney disease (CKD), but data are needed on their cost-effectiveness, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2023/05/12/7.htm
12 May 2023
Antihypertensive drugs reduced risk for new-onset type 2 diabetes; effect varies by antihypertensive class
The results of this individual-patient data meta-analysis suggest that angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers should be first-line antihypertensive agents in patients with prediabetes, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2022/04/08/7.htm
8 Apr 2022
In type 1 diabetes, real-time vs. intermittently scanned continuous glucose monitoring improved glycemic control
Clinicians can use the results of a recent European trial to reassure patients that good glycemic control can be achieved with either device, although real-time monitoring may be beneficial for those with more hypoglycemia issues, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2021/10/08/7.htm
8 Oct 2021